Skip to main content

Table 1 Clinical characteristics of PB-DHL patients (n = 48)

From: Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience

Variable DA-EPOCH-R/MA
(n, % )
DA-EPOCH-R
(n, % )
R-HyperCVAD
(n, % )
P value
Age     0.711
 ≤ 50 years 9 (64.3) 9 (50.0) 10 (62.5)  
 50–60 years 5 (35.7) 9 (50.0) 6 (37.5)  
Laterality     0.965
 Right 4 (28.6) 7 (38.9) 5 (31.3)  
 Left 7 (50.0) 8 (44.4) 7 (43.8)  
 Bilateral 3 (21.4) 3 (16.7) 4 (25.0)  
Tumour size     0.811
 < 5 cm 8 (57.1) 11 (61.1) 11 (68.8)  
 ≥ 5 cm 6 (42.9) 7 (38.9) 5 (31.3)  
Cell of origin     0.890
 GCB 11 (78.6) 15 (83.3) 14 (87.5)  
 Non-GCB 3 (21.4) 3 (16.7) 2 (12.5)  
Results of FISH     0.745
 MYC-BCL2 10 (71.4) 15 (83.3) 13 (81.3)  
 MYC-BCL6 4 (28.6) 3 (16.7) 3 (18.8)  
C-MYC of IHC     1.000
 C-MYC (+) 14 (100.0) 18 (100.0) 16 (100.0)  
BCL2 of IHC    0.521
 BCL2 (+) 13 (92.9) 18 (100.0) 15 (93.8)  
BCL6 of IHC     0.767
 BCL6 (+) 14 (100.0) 16 (88.9) 15 (93.8)  
CD5 of IHC     0.406
 CD5 (+) 5 (35.7) 4 (22.2) 7 (43.8)  
CD10 of IHC     0.661
 CD10 (+) 10 (71.4) 10 (55.6) 9 (56.3)  
P53 of IHC     0.926
 P53 (+) 9 (64.3) 13 (72.2) 11 (68.8)  
Ki-67 of IHC     0.668
 Ki-67 ≥ 70 % 12 (85.7) 17 (94.4) 15 (93.8)  
Chromosomal abnormality     0.700
 Present 3 (21.4) 6 (33.3) 3 (18.8)  
Ann Arbor Staging     0.832
 IE 4 (28.6) 6 (33.3) 3 (18.8)  
 IIE 7 (50.0) 7 (38.9) 7 (43.8)  
 IV 3 (21.4) 5 (27.8) 6 (37.5)  
B symptoms     0.652
 Present 10 (71.4) 10 (55.6) 10 (62.5)  
LDH level     0.544
 Elevated 5 (35.7) 7 (38.9) 9 (56.3)  
Risk stratification     0.665
  L and L-I 9 (64.3) 9 (50.0) 9 (56.3)  
 H and H-I 5 (35.7) 9 (50.0) 7 (43.8)  
ASCT     0.811
 Yes 6 (42.9) 7 (38.9) 5 (31.3)  
  1. PB-DHL primary breast double-hit lymphoma, R-HyperCVAD rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with cytarabine plus methotrexate, DA-EPOCH-R rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, DA-EPOCH-R/MA rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, alternating with high-dose methotrexate and cytarabine, FISH fluorescence in situ hybridization, IHC immunohistochemistry, LDH lactate dehydrogenase, GCB germinal centre B-cell, L low risk, L-I low-intermediate risk H-I high-intermediate risk, H high risk, ASCT autologous stem cell transplantation